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Abstract: We assessed a set of biological (HDL, LDL, SGOT,SGPT, GGT, HTc, Hb and T 
levels)  and  psychometric  variables  (investigated  through  HAM-D,  HAM-A,  GAS, 
Liebowitz Social Anxiety Scale, Mark & Mathews Scale, Leyton scale, and Pilowski scale) 
in  a  sample  of  64  alcohol  dependent  patients,  at  baseline  and  after  a  detoxification 
treatment.  Moreover,  we  recruited  47  non-consanguineous  relatives  who  did  not  suffer 
alcohol related disorders and underwent the same tests. In both groups we genotyped 11 
genetic variations (rs1800587; rs3087258; rs1799724; 5-HTTLPR; rs1386493; rs1386494; 
rs1487275; rs1843809; rs4570625; rs2129575; rs6313) located in genes whose impact on 
alcohol  related  behaviors  and  disorders  has  been  hypothesized  (IL1A,  IL1B,  TNF,  
5-HTTLPR, TPH2 and HTR2A). We analyzed the epistasis of these genetic variations upon 
the biological and psychological dimensions in the cases and their relatives. Further on, we 
analyzed the effects of the combined genetic variations on the short – term detoxification 
treatment efficacy. Finally, being the only not yet investigated variation within this sample, 
we analyzed the impact of the rs6313 alone on baseline assessment and treatment efficacy. 
We detected the following results: the couple rs6313 + rs2129575 affected the Leyton -Trait 
at  admission  (p  =  0.01)  (obsessive-compulsive  trait),  whilst  rs1800587  +  5-HTTLPR 
impacted the Pilowski test at admission (p = 0.01) (hypochondriac symptoms). These results 
did not survive Bonferroni correction (p ≤ 0.004). This lack of association may depend on 
the incomplete gene coverage or on the small sample size which limited the power of the 
study. On the other hand, it may reflect a substantial absence of relevance of the genotype 
variants  toward  the  alcohol  related  investigated  dimensions.  Nonetheless,  the  marginal 
significance we detected could witness an  informative correlation worth  investigating  in 
larger samples. 
Keywords:  gene;  alcohol  dependence;  IL1A;  IL1B;  TNF;  5HTPR;  HTR2A;  TPH2; 
association 
 
Abbreviations: 5-HTTLPR = promoter of the gene of the serotonin transporter; CIDI = 
Composite International Diagnostic Interview; GAS = Global Assessment Scale; GGT = 
gamma-glutamyltransferase;  GMDR  =  general  multifactor  dimensionality  reduction; 
HAM-A = Hamilton Anxiety Rating Scale; HAM-D = Hamilton Depression Rating Scale; 
Hb  =  hemoglobin;  HDL  =  high  density  lipoprotein;  HTc  =  hematocrit;  HTR2A  = 
serotonin receptor 2A; IL1A = interleukin 1, alpha; IL1B = interleukin 1, beta; LDL = low 
density lipoprotein; MDR = multifactor dimensionality reduction; SCAN = Schedules for 
Clinical  Assessment  in  Neuropsychiatry;  SGOT  (or  AST)  =  glutamic  oxaloacetic 
transaminase;  SGPT  (or  ALT)  =  glutamic  pyruvic  transaminase;  T  levels  =  thyroid 
hormonal levels; T3 = Triiodothyronine; T4 = Thyroxine; TNF = tumor necrosis factor; 
TPH2 = tryptophan hydroxylase 2; TSH = Thyrotropin. 
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1. Introduction 
 
Genes coding  for: interleukin 1, alpha  (IL1A), interleukin 1,  beta (IL1B), tumor necrosis  factor 
(TNF), serotonin receptor 2A (HTR2A), the promoter of the serotonin transporter gene (5-HTTLPR) 
and tryptophan hydroxylase 2 (TPH2) are candidate genes whose deregulation is thought to be central 
to  psychiatric  disorders  [1].  In  particular,  the  relevance  of  the  serotonin  system  has  been  widely 
investigated  and  supported  in  psychopathology  [2,3],  and  related  to  the  molecular  disruptions 
associated  with  alcohol  related  disorders  [4,5].  Consistently,  the  genetic  variations  located  in  the 
promoter of the serotonin transporter has been convincingly found to regulate mood disorders [6] and 
alcohol  related  disorders  [7-9].  Conflicting  results [10,11]  have  further  stimulated  research  in  this 
direction. HTR2A plays as a key serotonin receptor: it is responsible for the post-synaptic activation 
upon  serotonin  transmission,  a  role  that  may  modulate  the  psychiatric-related  neuronal  
deregulations  [12].  Recent  evidence  supports  its  connection  with  alcohol  addiction  [13-15].  In 
particular, HTR2A A-1438G variation, which is in completely LD with the variation we investigated 
here (reviewed in [12]), was found to be associated with alcohol dependence [15] and tobacco smoking 
combined  or  not  with  alcohol  dependence  [13].  Furthermore,  HTR2A  rs6313,  which  regulates  the 
expression rate of HTR2A (reviewed in [12]), was found to be associated with alcohol abuse in male 
patients [14]. TPH2 is the brain specific rate limiting enzyme in the synthesis of serotonin [16], a role 
that candidates it as a modulator of the serotonin system orchestration. Recent reports discouraged the 
hypothesis of its participation to alcohol related behaviors [17-19]. IL1A and IL1B are mediators of the 
acute  phase  response,  some  genetic  variations  located  in  these  genes  have  been  associated  with 
depressive  symptomatology,  antidepressant  outcome  and  alcoholism  [20,21].  TNF  is  a  white  cell 
produced pro-inflammatory cytokine likely involved in depressive disorder [16] which has been poorly 
investigated  as  a  mediator  of  alcohol  related  psychiatric  disorders.  We  yet  investigated  a  set  of 
variations  located  in  the  IL1A  (rs1800587),  IL1B  (rs3087258),  TNF  (rs1799724),  5-HTTLPR  (5-
HTTLPR)  and  TPH2  (rs1386493;  rs1386494;  rs1487275;  rs1843809;  rs4570625;  rs2129575)  as 
modulators of alcohol related disruptions, both enzymatic  and psychometric  in previous published 
papers [22,23]: despite the relevance of these receptors and enzymes in the modulation of alcohol 
related phenotypes, we reported a lack of association. The reasons of this may be attributable to: lack 
of  power,  incomplete  coverage  of  genetic  mutations,  incomplete  analysis  of  epigenetic  events, 
incomplete analysis of socio-demographic events and so on. In particular, epistasis between gene may 
have  been  played  a  fundamental  role  which  remained  undiscovered  during  the  analysis  of  single 
mutations in previous papers we published on this sample. The aim of this paper is to challenge this 
particular limit of the previous publications on this sample [6,22] through the analysis of the epistasis 
between the set of variations yet singularly analyzed, also including a not yet investigated mutation 
(HTR2A rs6313) in the model. Further on, given that HTR2A rs6313 was not investigated as a single 
mutation in this sample of patients, we investigated the HTR2A rs6313 alone impact as a regulator of 
the biological and psychometric alcohol related variables.  
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2. Methods 
 
2.1. Inclusion and Exclusion Criteria 
 
To be included in the study patients had to fulfill the DSM-IV (Diagnostic and Statistical Manual of 
mental disorders) diagnostic criteria for alcohol abuse/dependence – “primary alcoholism” – they had 
to  have  no  recent  alcohol  intake  (average  period  of  abstinence  prior  to  the  admission  to  the  
clinic = 24.0 ±  12.2 h), and to give full voluntary consent to the study. Other inclusion criteria were: 
absence of serious physical illness (as assessed through physical examination and routine laboratory 
screening), absence of other drug abuse, age between 20 and 75 years old, absence of DSM-IV axis I 
co-morbidity. The presence of affective symptoms was not considered to be an exclusion criterion. 
Alcohol abusers who fulfilled the DSM-IV diagnosis of depressive disorder were excluded from the 
study in the case that a full diagnosed depressive episode was precedent to the onset of the alcohol 
dependence. Relatives (non-consanguineous) were included in the study if they did not meet criteria 
for  past  or  current  alcohol  abuse/dependence  and  major  medical  disturbances.  Written  informed 
consent was obtained from each participant after approval from the local ethical committee. Patients 
and their relatives were enrolled at the Drug and Alcohol Addiction Clinic of the Athens University 
Psychiatric Clinic at the Eginition Hospital  in  Athens, Greece. For patients, alcohol detoxification 
program included vitamin replacement (B, C, E) and oral administration of diazepam (10–40 mg daily 
in  divided  doses),  with  gradual  taper  off  over  a  week.  The  overall  period  of  detoxification  was 
completed in 4–5 weeks. Patients then followed an inpatient standard treatment program with a short-
term psychotherapy of cognitive-behavioral orientation.  
 
2.2. Assessment 
 
The biochemical profile of cholesterol,  high density  lipoprotein (HDL),  low density  lipoprotein 
(LDL),  glutamic  oxaloacetic  transaminase  (SGOT  or  AST),  serum  glutamic  pyruvic  transaminase 
(SGPT or ALT) and gamma-glutamyltransferase (GGT), were assessed once in relatives and twice in 
patients. Hematocrit, hemoglobin and thyroid hormonal levels (Triiodothyronine = T3, Thyroxine = T4, 
Thyrotropin  =  TSH)  were  measured  once  in  both  relatives  and  alcohol  dependents.  Patients  were 
evaluated  by  a  set  of  psychological  tests:  at  admission  they  were  evaluated  by  the  Schedules  for 
Clinical  Assessment  in  Neuropsychiatry  (SCAN  [24])  and  the  Composite  International  Diagnostic 
Interview (CIDI - section on alcohol consumption  [25]). Sociodemographic data were collected as 
well. Hamilton Depression Rating Scale (HAM-D) the Hamilton Anxiety Rating Scale (HAM-A) the 
Global Assessment Scale (GAS), the Liebowitz Social Anxiety Scale (social fear and avoidance) [26], 
the  Mark  &  Mathews  Scale  (general  fear)  [27],  the  Leyton  Obsessional  Inventory  [28],  and  the 
Pilowski  scale  (hypochondriac  symptoms)  [29]  were  administered  at  admission  and  discharge. 
Genotyping was performed as previously described [22].  
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2.3. Statistics 
 
Principal analysis 
 
In  the  principal  analysis  the  independent  variable  was  the  epistasis  between  the  investigated 
variations  (rs1800587;  rs3087258;  rs1799724;  5-HTTLPR;  rs1386493;  rs1386494;  rs1487275; 
rs1843809; rs4570625; rs2129575; rs6313). Diagnosis, biological and psychometric tests’ scores were 
treated as dependent variables of the principal analysis. Correlation analysis was employed in order to 
assess whether socio-demographic variables were associated with the dependent variables. In the event 
of  significant  association,  socio-demographic  variables  were  treated  as  covariates  in  the  principal 
analysis.  We  employed  GMDR  Software  Beta  version  0.7  to  investigate  the  gene  to  gene  
interactions  [30],  possible  confounders  were  included  in  the  analysis  accordingly  to  GMDR  
manual [30]. Gender and age were  included as possible confounders when analyzing cases  versus 
controls. Alpha value was conservatively set to 0.004 (Bonferroni correction: 0.05/11 polymorphisms). 
Power  was  sufficient  in  our  sample  to  detect  an  effect  size  of  d  =  0.88  or  similar  as  previously  
detailed [22]. The  multifactor dimensionality reduction (MDR)  method  [30] was employed  by the 
GMDR  Software  Beta  version  0.7  to  investigate  the  gene–gene  interactions.  The  MDR  model 
computes the data reducing the n-dimensional space formed by a given set to a single dimension to 
analyze n-way interactions. Each class is then classified as either high risk or low risk according to the 
relative proportion of cases to controls in that class. This is performed for all possible combinations of 
SNPs, and the combination with the best predictive capacity is identified. Accordingly to the settings 
of the software, we tested all the possible two- to six-loci interactions using 10-fold cross-validation in 
an exhaustive search, thus considering all possible SNP combinations. As outcome parameters we 
considered  the  testing  balanced  accuracy,  the  significance  test,  along  with  the  test  sensitivity  and 
specificity. The testing balanced accuracy  measures the degree to which the  interaction accurately 
predicts case–control status (label 1 indicating good prediction of the model, label 0.50 suggesting that 
the model is no better than chance in selecting cases from controls). The significance test gives the p 
value of the calculation. 
 
Secondary analysis 
 
In the secondary analysis the independent variable was: rs6313 genotypes. Diagnosis, biological 
and  psychometric  tests’  scores  were treated  as dependent  variables.  Chi-square  test,  ANOVA  and 
ANCOVA analyses were employed when needed in order to infer the impact of rs6313 genotypes on 
the dependent variables (diagnosis, biological and psychometric tests’ scores).  
 
3. Results 
 
Sixty four alcohol dependent patients and 47 relatives (non-consanguineous) were included in the 
study.  Patients’  and  their  relatives’  characteristics  are  reported  in  Table  1.  Table  2  reports  the 
psychological assessment at admission and discharge. Biochemical reports are detailed in [22]. As a 
result of the principal analysis, that is, the interaction between epistasis (independent variable) and Int. J. Environ. Res. Public Health 2009, 6                 
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diagnosis and psychometric tests’ scores (dependent variable), we found a marginal impact of HTR2A 
rs6313  +  TPH2  rs2129575  on  Leyton  -Trait  at  admission  (p  =  0.01;  test  accuracy  =  0.87;  test 
sensitivity  =  0.95;  test  specificity  =  0.56)  and  a  similar  marginal  impact  of  ILA  rs1800587  +  5-
HTTLPR on Pilowski test at admission (p = 0.01; test accuracy = 0.80; test sensitivity = 0.73; test 
specificity = 0.85).  
Table 1. Demographic data of patients. 
Variable  Total  Females  Males 
Sex   Cases = 64 (100%) 
Controls = 47 (100%) 
Cases = 15 (21%) 
Controls = 39 (52%) 
Cases = 49 (79%) 
Controls = 8 (48%)  
Age (years)  Cases = 45.60 ±  9.89 
Controls = 47 ±  11.52 
Cases = 45.42 ±  9.96 
Controls = 48.79 ±  10.98 
Cases = 45.64 ±  9.94 
Controls = 43.87 ±  13.96 
Weight (kg)  74.42 ±  11.45  62.94 ±  0.96  77.11 ±  9.83 
Alcohol (gr/day)  265.27 ±  138.32  152.32 ±  55.66  291.77 ±  138.7 
Age of onset  26.91 ±  10.14  29 ±  8.75  26.42 ±  10.45 
Smoking (cigs/day)  11.40 ±  15.84  9.74 ±  10.47  11.79 ±  16.89 
 
Table 2. Psychopathological assessment: admission and discharge. 
Variable  Admission  2nd week  3rd week  4th week  P (adm vs 
4th week) 
HDRS  39.45 ±  6.86  31.35 ±  7.11  14.5 ±  6.81  6.65 ±  5.20  < 0.001 
HARS  34.44 ±  9.80  27.54 ±  8.47  14.35 ±  7.11  6.71 ±  5.29  < 0.001 
GAS  46.30 ±  5.06  56.7 ±  5.51  74.3 ±  8.68  83.90 ±  8.27  < 0.001 
Liebowitz Social Anxiety 
Scale (social fear) 
51 ±  9.45  -  -  30.16 ±  6.04  < 0.001 
Liebowitz Social Anxiety 
Scale (social avoidance) 
54.91 ±  11.04  -  -  31.89 ±  7.63  < 0.001 
Mark & Mathews Scale  49.30 ±  11.59  -  -  18.86 ±  5.91  < 0.001 
Leyton Obsessional 
Inventory 
14.5 ±  3.34  -  -  10.04 ±  3.17  < 0.001 
Pilowski scale  9.14 ±  2.72  -  -  4.92 ±  2.16  < 0.001 
 
The results are shown in Figure 1: the frequencies of combined genotypes which have been found to 
be significantly associated with the scores of the dependent variables are in grey boxes; positive scores 
upon the right column in every box represent the frequencies of combined genotypes that have been 
associated with higher scores at the investigated test, negative scores upon each left column in each 
box  represent  the  frequencies  of  the  combined  genotypes  which  have  been  associated  with  lower 
scores  at  the  investigated  test.  Higher  and  lower  scores  are  defined  accordingly  to  the  normal 
distribution  obtained  from  the  analysis  of  input  data,  “0”  corresponding  to  the  mean  value  of 
dependent  variable,  positive  scores  corresponding  to  scores  upon  the  mean  and  negative  scores 
corresponding  to  scores  below  the  mean  in  the  sample.  Light  boxes  represent  not  significant 
associations. These results did not survive the Bonferroni correction. In the secondary analysis of the 
study, rs6313 did not impact the psychopathologic dimension and did not separate patients from their 
relatives (data not shown). In the pictures the grey shadowed boxes designate the combinations of 
genotypes associated with a statistically significant different distribution of the scores of the test under 
investigation. The light shadowed boxes designate the combinations of genotypes associated with a 
non statistically significant different distribution of the scores of the test under investigation.  Int. J. Environ. Res. Public Health 2009, 6                 
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Figure 1. Marginal significant epistasis results. 
 
(p = 0.01; test accuracy = 0.80; test sensitivity = 0.73; test specificity = 0.85) 
 
 
(p = 0.01; test accuracy = 0.87; test sensitivity = 0.95; test specificity = 0.56) 
 
Dark gray cells = the combinations for which the combined frequencies of genotypes can significantly 
predict the distribution of the dependent variable. 
Light gray cells = the combinations that cannot predict the distributions of the dependent variable.  
Bars in each box = the frequency of the combined genotypes are separated on the basis of the dependent 
variable into two groups, being the mean score of the dependent variable the threshold between them. 
Numbers  upon  each  column = given that the dependent variable was implemented as a normalized 
distribution with “0” as mean and threshold value, columns on the left in each box are labeled as positive, 
and columns  on the right  of  each box are labeled as negative. Absolute numbers upon  each column 
represent the frequency of each combined genotype. 
Effect on Pilowski test at 
admission 
Effect on Leyton -Trait at 
admission Int. J. Environ. Res. Public Health 2009, 6                 
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To be implemented in the GMDR software the scores were normalized with “0” as the mean and 
threshold value. The GMDR software computes the frequencies of subjects who score higher (positive 
values on the left column on each box) or lower (negative values on the right column on each box) 
than “0” which is representative of the mean of the scores at the test under investigation. The scores 
are differentiated in positive and negative: the mean score given as a threshold, the positive scores 
stand for subjects who ranked higher than the mean, the negative stand for subjects who ranked lower 
than the mean. The difference in the frequencies of positive and negative scoring subjects is labeled as 
significant in the grey shadowed boxes. Light shadowed boxes stand for not significant difference in 
distribution of positive and negative scores. For example, in the first picture it is shown that IL1A 
rs1800587  and  5-HTTLPR  combined  variations  are  associated  with  a  significant  different  score at 
Pilowski  test  at  admission  only  in  some  specific  combination  of  genotypes:  the  genotype  CC  at 
rs1800587 is associated with higher frequencies of subjects who ranked higher than the mean of the 
Pilowski  test,  only  when  it  is  found  to  be  in  combination  with  the  LL  or  SS  genotypes  at  the  
5-HTTLPR. On the other hand, the combination with heterozygosis at the 5-HTTLPR with the same 
genotype at rs1800587 resulted in a not significant different distribution of subjects who ranked higher 
or lower than the mean of the Pilowski test. In the second picture, the combination of the CT genotype 
at rs6313 and the GG genotype at rs2129575 results into statistically significant higher scores at the 
Leyton  –  Trait  test  at  admission,  along  with  the  other  combinations  of  genotypes  which  are  
grey shadowed. 
 
4. Discussion  
 
We  found a  marginal  impact of the epistatic effect between the  investigated variations and the 
obsessive-compulsive traits and hypochondriac symptoms. The low level of significance which did not 
stand the Bonferroni correction, is likely mainly related to the small sample size we investigated here: 
as  formerly reported, the power was sufficient to detect a large effect size. Moreover, the genetic 
analysis we performed here did not cover the genes that are under investigation, which results in a 
possible genetic bias: some variations remain hidden in the present investigation that could impact the 
functionality of the investigated mutations. This exposes our study to a biological stratification bias 
which is quite common in literature [31]. Finally, the most part of the investigated variations belong to 
the  TPH2  gene  which  has  been  quite  consistently  reported  to  be  not  associated  with  alcohol 
dependence. In all facts, even though TPH2 is the rate limiting enzyme for the synthesis of serotonin in 
central nervous system [32], a molecular role that candidates it as a central regulator of psychiatric 
disorders  such  as  major  depressive  disorder  [33-35]  and  bipolar  disorder  [35-37],  recent  reports 
rejected  the  hypothesis  that  variations  located  in  the  TPH2  gene  could  modulate  alcohol  
dependence [17-19]. This is in contrast with the inhibitory role played by the serotonin system toward 
the  mesolimbic  dopaminergic  system  [38,39]  which  is  thought  to  be  primarily  involved  in  the 
disruptions  that  lead  to  alcohol  dependence  [5].  This  is  the  biological  evidence  that  steered  our 
attention on the possible epistasis impact of some relevant and well replicated variants (5-HTTLPR and 
HTR2A rs6313) over a putative good candidate as the TPH2 is. Some recent reports on the significant 
epistasis interaction between genetic variables that did not cast informative results when singularly 
investigated [40,41], convinced us to re-analyze our previously published results. Unfortunately, we Int. J. Environ. Res. Public Health 2009, 6                 
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could only find not conclusive data in this specific case. The question arises as whether the marginal 
significant associations we report are false positive findings, which are a common concern in genetic 
association studies [42], or the first partial evidence of a significant association.  
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